Rifapentine Capsules

Rifapentine is a semi-synthetic broad-spectrum bactericidal agent with strong antibacterial activity against Mycobacterium tuberculosis in vitro, with a minimum inhibitory concentration (MIC) of 0.12-0.25 mg/L, which is 2-10 times stronger than rifampicin; its anti-tuberculosis infection effect in mice is also better than rifampicin. Mycobacterium leprae and other mycobacteria such as Mycobacterium kansasii and Mycobacterium toad are also sensitive to this product, but Mycobacterium avium is resistant. In addition, this product has high antibacterial activity against most Gram-positive cocci, with a MIC of <0.025 mg/L; it has poor effect on Gram-negative bacteria. Its effect on Chlamydia is similar to that of erythromycin and doxycycline, but worse than rifampicin; it has poor effect on methicillin-resistant Staphylococcus aureus. In vitro test results show that Chlamydia, Staphylococcus aureus and Neisseria gonorrhoeae are all

The main ingredient of this product is rifapentine, whose chemical name is 3-[[(4-cyclopentyl-1-piperazinyl)imino]methyl]-rifamycin. Chemical structure: Molecular formula: C47H64N4O12 Molecular weight: 877.04

This product is in the form of capsules.

1. This product is used in combination with other anti-tuberculosis drugs for the initial and retreatment treatment of various tuberculosis, but it is not suitable for the treatment of tuberculous meningitis. 2. It is suitable for short-term chemotherapy under direct observation by medical staff. 3. It can also be used for the treatment of non-tuberculous mycobacterial infections. 4. It may be effective in the treatment of leprosy in combination with other anti-leprosy drugs;

Oral, anti-tuberculosis. Adults take 0.6g at a time (those weighing <55kg should take less), once a day, on an empty stomach (1 hour before meals) with water; take 1-2 times a week. It needs to be used in combination with other anti-tuberculosis drugs. The treatment course for initial pulmonary tuberculosis patients is generally 6-9 months.

The adverse reactions of this product are milder than those of rifampicin. In a few cases, leukopenia and thrombocytopenia, elevated alanine aminotransferase, rash, dizziness, insomnia, etc. are seen. Gastrointestinal reactions are rare. No influenza syndrome, immune thrombocytopenia, or anaphylactic shock-like reactions were found in the use of this product. If such adverse reactions occur, the drug must be discontinued immediately.

1. Patients who are allergic to this product or rifamycin antibiotics are contraindicated. 2. Patients with severe liver dysfunction, biliary obstruction and pregnant women are contraindicated.

Precautions for children: The safety of this product in children under 5 years old has not been determined. Precautions for pregnancy and lactation: Pregnant women are prohibited from using this product because it can be excreted through breast milk. Lactating women should fully weigh the pros and cons before deciding whether to use the drug. If this product is needed, breastfeeding should be suspended. Precautions for the elderly: Elderly patients have decreased liver function and the dosage should be reduced as appropriate.

1. Drinking alcohol every day while taking this product may increase the hepatotoxicity of this product, so you should abstain from alcohol while taking this product. 2. Para-aminosalicylate may affect the absorption of this product, resulting in a decrease in its blood concentration; if it must be used together, the interval between taking the two should be at least 6 hours. 3. Phenobarbital drugs may affect the absorption of this product, so it is not suitable to be taken with this product at the same time. 4. When this product is used simultaneously with oral anticoagulants, the latter's anticoagulant effect will be reduced, so attention should be paid. 5. The combination of this product with isoniazid may increase the risk of hepatotoxicity, especially in patients with existing liver damage and patients with rapid acetylation of isoniazid. 6. The combination of this product with ethionamide may aggravate its adverse reactions. 7. The combined use of antacids will significantly reduce the bioavailability of this product. 8

Keep away from light and store in sealed container.

0.15g

Hebei Aier Haitai Pharmaceutical Co., Ltd.

• Founded in:

  2006-03-07

• Address:

  No. 219, Taishan Street, Shijiazhuang High-tech Industrial Development Zone

• Tax NO.:

  91130101785718732X

• Registered Funds:

  55.1622 million yuan

• Website:

  Log in to view

• Email:

  Log in to view